Sirin Falconi1†
Palika Datta
Kaytlin Krutsch
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1School of Medicine, Texas Tech University Health Sciences Center, Amarillo, TX, United States
- 2Department of Obstetrics and Gynecology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, United States
- 3Department of Cardiology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, United States
- 4Department of Obstetrics and Gynecology, School of Medicine, Texas Tech University Health Sciences Center, Amarillo, TX, United States
A Corrigendum on
The concentration of maternal sacubitril/valsartan transferred into human milk is negligible
by Falconi, S., Okimi, A., Wesley, S., Sethi, P., Datta, P., and Krutsch, K. (2024). Front. Public Health. 12:1389513. doi: 10.3389/fpubh.2024.1389513
In the published article, there was an error. The currently published article does not acknowledge a previously published study. We would like to add the missing data and properly reference the earlier work.
A correction has been made to Discussion, paragraph one.
This sentence previously stated:
“There are no previous studies evaluating the transfer of any NEP inhibitor (e.g., sacubitril) or ARB (e.g., valsartan) into human milk, limiting the use of these drug classes in breastfeeding mothers suffering from HF.”
The corrected sentence appears below:
“There are no previous studies evaluating the transfer of any NEP inhibitor (e.g., sacubitril) into human milk. A single case series has reported the limited transfer of one ARB, candesartan, into human milk (25). This scarcity of data restricts the use of these drug classes in breastfeeding mothers suffering from HF.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Keywords: heart failure, entresto, lactation, pharmacology, peripartum cardiomyopathy (PPCM), maternal health
Citation: Falconi S, Okimi A, Wesley S, Sethi P, Datta P and Krutsch K (2024) Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible. Front. Public Health 12:1517339. doi: 10.3389/fpubh.2024.1517339
Received: 25 October 2024; Accepted: 31 October 2024;
Published: 13 November 2024.
Edited and reviewed by: Charlotte Cosemans, University of Hasselt, Belgium
Copyright © 2024 Falconi, Okimi, Wesley, Sethi, Datta and Krutsch. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kaytlin Krutsch, S2F5dGxpbi5LcnV0c2NoQHR0dWhzYy5lZHU=
†These authors have contributed equally to this work